These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 25683938)

  • 1. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
    Kan X; Jing Y; Wan QY; Pan JC; Han M; Yang Y; Zhu M; Wang Q; Liu KH
    Eur Rev Med Pharmacol Sci; 2015; 19(2):247-55. PubMed ID: 25683938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
    Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
    Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
    Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
    Zhu K; Huang J; Lai L; Huang W; Cai M; Zhou J; Guo Y; Chen J
    Radiology; 2018 Jul; 288(1):300-307. PubMed ID: 29688153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
    Giorgio A; Merola MG; Montesarchio L; Merola F; Santoro B; Coppola C; Gatti P; Amendola F; DI Sarno A; Calvanese A; Matteucci P; Giorgio V
    Anticancer Res; 2016 Nov; 36(11):6179-6183. PubMed ID: 27793949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
    Fukuda H; Numata K; Moriya S; Shimoyama Y; Ishii T; Nozaki A; Kondo M; Morimoto M; Maeda S; Sakamaki K; Morita S; Tanaka K
    Radiology; 2014 Aug; 272(2):598-604. PubMed ID: 24689883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
    Park JG; Park SY; Lee HW
    World J Gastroenterol; 2015 Feb; 21(8):2568-72. PubMed ID: 25741170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
    Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
    Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
    Liang HY; Lu LG; Hu BS; Li Y; Shao PJ
    Chin Med J (Engl); 2013 Nov; 126(22):4270-6. PubMed ID: 24238511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib combined with radiofrequency ablation in the treatment of a patient with renal cell carcinoma plus primary hepatocellular carcinoma.
    Gang G; Hongkai Y; Xu Z
    J Cancer Res Ther; 2015; 11(4):1026. PubMed ID: 26881596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
    Li Y; Zheng YB; Zhao W; Liu B; Hu BS; He X; Huang JW; Lu LG
    Med Oncol; 2013 Dec; 30(4):730. PubMed ID: 24048774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
    Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Park JG
    Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.